On 8 June 2026, the European Medicines Agency (EMA) published its monthly overview of applications for new human medicines that are currently under evaluation. The document lists the active substances, therapeutic areas, and types of applications (e.g., marketing authorisation, extension of indication) that the EMA's Committee for Medicinal Products for Human Use (CHMP) will assess in the coming months. The publication is part of EMA's routine transparency measures to inform stakeholders about upcoming regulatory decisions.
The document provides a snapshot of the pipeline for innovative and generic medicines, covering a range of therapeutic areas including oncology, neurology, and rare diseases. Each entry includes the applicant company, the proposed indication, and the expected timeline for the CHMP opinion. The list is updated monthly and serves as a planning tool for healthcare professionals, investors, and patient organisations.
Impact on stakeholders For pharmaceutical companies, the publication offers early visibility into which products are progressing toward potential market approval, allowing them to prepare for launch activities and competitive positioning. For patients and healthcare providers, the list signals which new therapies may become available in the EU within the next year, particularly for unmet medical needs. National health technology assessment (HTA) bodies can use the information to begin early evaluation of cost-effectiveness and budget impact. However, the list does not guarantee approval; the CHMP may request additional data or issue a negative opinion, which could delay or block market access.
Regulatory context The June 2026 list includes several applications for advanced therapy medicinal products (ATMPs) and biosimilars, reflecting EMA's ongoing focus on facilitating access to innovative treatments while ensuring safety and efficacy. The agency has recently streamlined procedures for orphan medicines and accelerated assessments for products addressing public health emergencies. The publication also highlights EMA's commitment to transparency, as the list is made publicly available without charge.
Expected follow-up The CHMP will issue its opinions on these applications during its monthly meetings, typically within 210 days for standard procedures. Negative opinions or requests for additional data will be communicated separately. Stakeholders are encouraged to monitor EMA's website for updates and to participate in public consultations when applicable.
← Atlas › News › Health & Lifestyle